NOVI, Mich.--(BUSINESS WIRE)--Delphinus Medical Technologies, Inc., the leader in advanced breast ultrasound technology, will be gathering subject experts to discuss recent legislation and new technology affecting women with dense breasts during RSNA 2017 in Chicago. On Tuesday, Nov. 28, from 11 am to 1 pm CST, the company will host Nancy Cappello, Ph.D., director and founder of Are You Dense, Inc. and Are You Dense Advocacy, Inc. at its booth 3353. Mary Yamashita, M.D., assistant professor of clinical radiology at USC Norris Comprehensive Cancer Center and the national principal investigator of the SoftVue Discover Breast Ultrasound project, will also be at the Delphinus exhibit during the conference.
More than 40 percent1 of women nationwide have dense breast tissue, which is unrelated to weight or breast size. Because dense breasts can mask potential cancers on mammography, the sensitivity for detecting cancer is lower in women with dense breasts.
“We are thrilled to be hosting Dr. Nancy Cappello and Dr. Mary Yamashita in our exhibit at this year’s RSNA meeting,” said Mark Forchette, CEO of Delphinus. “It’s an ideal forum to discuss unmet patient needs in dense breast screening. Together, we must work to advance clinical thought and practice to serve women with dense breasts better.”
- Nancy Cappello, Ph.D., founded Are You Dense, Inc., and Are You Dense Advocacy, Inc. with a mission to educate the public about the risks and screening challenges of dense breast tissue to prevent missed, delayed, and advanced-stage cancer, thus reducing mortality. She is the inspiration behind Connecticut’s first-in-the-nation density reporting law passed in 2009, making the state a global leader in density reporting, adjunct screening, and the density reporting grassroots movement. Thirty-one states have since enacted density reporting laws and a federal bill is pending. Dr. Cappello will be on hand at RSNA to speak to attendees about state legislation and the recent reintroduction of federal density reporting bill and its potential impact on breast screening in the U.S., particularly to women with dense breast tissue.
- Dr. Mary Yamashita will be available to discuss her experience as principal investigator of SoftVue Discover Breast Ultrasound, a 10,000 patient research project that will measure the effectiveness of Delphinus’ SoftVue 3D whole breast ultrasound system in detecting additional cancers that are not seen with mammography alone. The project is currently enrolling asymptomatic women with dense breast tissue at seven sites across the U.S.
About Delphinus Medical Technologies, Inc.
Headquartered in Novi, Michigan, Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue™, the first circular array transducer technology that has received sequential U.S. Food and Drug Administration clearances. The patented technology is a 3D whole breast ultrasound imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. SoftVue™ is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography. Delphinus was founded as a spin out of the Karmanos Cancer Institute in Detroit and is capitalized through principal investments by Arboretum Ventures, Ann Arbor, Mich., Beringea, Farmington Hills, Mich., North Coast Technology Investors, Ann Arbor, Mich., Venture Investors, Madison, Wis., Hopen Life Science Ventures, Grand Rapids, Mich., and Waycross Ventures, Menlo Park, Calif. For more information, visit www.delphinusmt.com.
* SoftVue™ is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography.
1 Sprague BL, et al. Prevalence of Mammographically Dense Breasts in the United States. J Natl Cancer Inst. 2014 Oct; 106(10): dju255. Published online 2014 Sep 12.